Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 58

1.

Regression Analysis of Protoporphyrin IX Measurements Obtained During Dermatological Photodynamic Therapy.

Tyrrell J, Paterson C, Curnow A.

Cancers (Basel). 2019 Jan 10;11(1). pii: E72. doi: 10.3390/cancers11010072.

2.

Improving In Vitro Photodynamic Therapy through the Development of a Novel Iron Chelating Aminolaevulinic Acid Prodrug.

Curnow A, Perry A, Wood M.

Photodiagnosis Photodyn Ther. 2018 Dec 13. pii: S1572-1000(18)30331-4. doi: 10.1016/j.pdpdt.2018.12.005. [Epub ahead of print]

3.

Altered cellular redox homeostasis and redox responses under standard oxygen cell culture conditions versus physioxia.

Ferguson DCJ, Smerdon GR, Harries LW, Dodd NJF, Murphy MP, Curnow A, Winyard PG.

Free Radic Biol Med. 2018 Oct;126:322-333. doi: 10.1016/j.freeradbiomed.2018.08.025. Epub 2018 Aug 22.

4.

An experimental investigation of a novel iron chelating protoporphyrin IX prodrug for the enhancement of photodynamic therapy.

Anayo L, Magnussen A, Perry A, Wood M, Curnow A.

Lasers Surg Med. 2018 Jul;50(5):552-565. doi: 10.1002/lsm.22809. Epub 2018 Mar 31.

5.

Stress and Unusual Events Exacerbate Symptoms in Menière's Disease: A Longitudinal Study.

Yeo NL, White MP, Ronan N, Whinney DJ, Curnow A, Tyrrell J.

Otol Neurotol. 2018 Jan;39(1):73-81. doi: 10.1097/MAO.0000000000001592.

PMID:
29065087
6.

Diagnosis of Chronic Intestinal Pseudo-obstruction and Megacystis by Sequencing the ACTG2 Gene.

Milunsky A, Baldwin C, Zhang X, Primack D, Curnow A, Milunsky J.

J Pediatr Gastroenterol Nutr. 2017 Oct;65(4):384-387. doi: 10.1097/MPG.0000000000001608.

7.

The hydroxypyridinone iron chelator CP94 increases methyl-aminolevulinate-based photodynamic cell killing by increasing the generation of reactive oxygen species.

Dogra Y, Ferguson DCJ, Dodd NJF, Smerdon GR, Curnow A, Winyard PG.

Redox Biol. 2016 Oct;9:90-99. doi: 10.1016/j.redox.2016.07.002. Epub 2016 Jul 7.

9.

The effects of protoporphyrin IX-induced photodynamic therapy with and without iron chelation on human squamous carcinoma cells cultured under normoxic, hypoxic and hyperoxic conditions.

Blake E, Allen J, Curnow A.

Photodiagnosis Photodyn Ther. 2013 Dec;10(4):575-82. doi: 10.1016/j.pdpdt.2013.06.006. Epub 2013 Aug 8.

PMID:
24284114
10.

The cellular and molecular carcinogenic effects of radon exposure: a review.

Robertson A, Allen J, Laney R, Curnow A.

Int J Mol Sci. 2013 Jul 5;14(7):14024-63. doi: 10.3390/ijms140714024. Review.

11.

Mutations in PDYN are not responsible for multiple system atrophy.

Fogel BL, Baker C, Curnow A, Perlman SL, Geschwind DH, Coppola G.

J Neurol. 2013 Mar;260(3):927-8. doi: 10.1007/s00415-012-6830-x. Epub 2013 Jan 25. No abstract available.

12.

The time-dependent accumulation of protoporphyrin IX fluorescence in nodular basal cell carcinoma following application of methyl aminolevulinate with an oxygen pressure injection device.

Blake E, Campbell S, Allen J, Mathew J, Helliwell P, Curnow A.

J Photochem Photobiol B. 2012 Dec 5;117:97-103. doi: 10.1016/j.jphotobiol.2012.09.002. Epub 2012 Sep 18.

PMID:
23092624
13.

Effect of an oxygen pressure injection (OPI) device on the oxygen saturation of patients during dermatological methyl aminolevulinate photodynamic therapy.

Blake E, Allen J, Thorn C, Shore A, Curnow A.

Lasers Med Sci. 2013 May;28(3):997-1005. doi: 10.1007/s10103-012-1188-y. Epub 2012 Aug 28.

PMID:
22926533
14.

Radon and skin cancer in southwest England: an ecologic study.

Wheeler BW, Allen J, Depledge MH, Curnow A.

Epidemiology. 2012 Jan;23(1):44-52. doi: 10.1097/EDE.0b013e31823b6139.

PMID:
22081061
15.

An in vitro comparison of the effects of the iron-chelating agents, CP94 and dexrazoxane, on protoporphyrin IX accumulation for photodynamic therapy and/or fluorescence guided resection.

Blake E, Allen J, Curnow A.

Photochem Photobiol. 2011 Nov-Dec;87(6):1419-26. doi: 10.1111/j.1751-1097.2011.00985.x. Epub 2011 Sep 16.

PMID:
21834866
16.

Oxygen saturation and perfusion changes during dermatological methylaminolaevulinate photodynamic therapy.

Tyrrell J, Thorn C, Shore A, Campbell S, Curnow A.

Br J Dermatol. 2011 Dec;165(6):1323-31. doi: 10.1111/j.1365-2133.2011.10554.x. Epub 2011 Nov 17.

PMID:
21801159
17.

Comparison of protoporphyrin IX accumulation and destruction during methylaminolevulinate photodynamic therapy of skin tumours located at acral and nonacral sites.

Tyrrell JS, Morton C, Campbell SM, Curnow A.

Br J Dermatol. 2011 Jun;164(6):1362-8. doi: 10.1111/j.1365-2133.2011.10265.x. Epub 2011 May 13.

PMID:
21564050
18.
19.

The effect of air cooling pain relief on protoporphyrin IX photobleaching and clinical efficacy during dermatological photodynamic therapy.

Tyrrell J, Campbell SM, Curnow A.

J Photochem Photobiol B. 2011 Apr 4;103(1):1-7. doi: 10.1016/j.jphotobiol.2010.12.011. Epub 2010 Dec 28.

PMID:
21277787
20.

Protoporphyrin IX photobleaching during the light irradiation phase of standard dermatological methyl-aminolevulinate photodynamic therapy.

Tyrrell J, Campbell S, Curnow A.

Photodiagnosis Photodyn Ther. 2010 Dec;7(4):232-8. doi: 10.1016/j.pdpdt.2010.09.005. Epub 2010 Nov 5.

PMID:
21112545

Supplemental Content

Loading ...
Support Center